Experimental prostate cancer vaccine shows promise in early trial

NCT ID NCT05617040

Terminated Disease control Sponsor: Barinthus Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 21, 2026 · Updated 28 times

Summary

This study tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned after initial treatment (surgery or radiation). The goal was to see if the treatment was safe and could lower PSA levels, a marker of cancer activity. The trial was terminated early, but results help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Cornell University

New York, New York, 10065-4805, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER